A Phase 3, Randomized, Modified Double-blind, Active-controlled, Parallel-group, 2-arm Study to Investigate the Safety and Immunogenicity of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants and Toddlers
Latest Information Update: 06 Mar 2026
At a glance
- Drugs SP-0202 (Primary) ; Hib-DTaP-hepatitis B-poliovirus vaccine
- Indications Pneumococcal infections
- Focus Registrational; Therapeutic Use
- Sponsors Sanofi
Most Recent Events
- 02 Mar 2026 Planned End Date changed from 31 Aug 2027 to 25 Aug 2027.
- 02 Mar 2026 Planned primary completion date changed from 31 Aug 2027 to 25 Aug 2027.
- 02 Mar 2026 Status changed from recruiting to active, no longer recruiting.